CREDIT ANALYSIS: INCEPTUA LIMITED

1. Credit Opinion: CONDITIONAL

Rationale: Inceptua Limited presents a fundamentally transformed credit profile following a remarkable turnaround from negative equity of £2.9M (2022) to positive net assets of £1.2M (2024). The company operates within a supportive group structure (Inceptua SA, Switzerland) and maintains healthy cash reserves of £4.2M. However, the significant decline in pre-tax profit from £3.28M (2023) to £1.28M (2024)—a 61% drop—alongside a near-doubling of administrative expenses, introduces uncertainty regarding earnings sustainability. Credit facilities should be considered with appropriate covenants and monitoring.

2. Financial Strength

Equity Position – Dramatic Improvement The balance sheet has undergone substantial rehabilitation:

This represents a £4.1M swing over two years, moving from deeply insolvent to a modestly capitalised position. The improvement appears driven by retained profits and likely group capital support, though the exact mechanism requires clarification.

Leverage Assessment - Total liabilities reduced from £268,517 (2023) to £174,257 (2024) - Debt-to-equity ratio has improved significantly as equity has grown - Share capital stands at £100,000, indicating retained earnings form the primary equity base

Group Support Framework The strategic report confirms that Inceptua SA, the Swiss parent, is obligated under a cost allocation agreement to cover shared service and function-related expenses. This provides meaningful downside protection, though the enforceability and financial capacity of the parent should be verified.

3. Cash Flow Assessment

Liquidity Position – Strong - Cash reserves: £4,243,123 (2024) vs £3,340,101 (2023)—a 27% increase - Net current assets: £1,078,434 (2024) vs £227,922 (2023)—a substantial improvement - Current ratio appears comfortable given the net current asset position

Working Capital Concerns Trade creditors represent 136 days of purchases—significantly above typical pharmaceutical wholesale norms (30-60 days). This may indicate: - Extended supplier payment terms as a cash management strategy - Potential strain on supplier relationships - Reliance on inter-company payables (noted in the report)

Profitability Trajectory – Mixed Signals

The dramatic improvement in gross profit (gross margin rising from ~7% to ~21%) is offset by administrative expenses increasing from £5.98M to £12.86M. This warrants investigation—it may reflect investment in the Early Access and Inceptua Pharma business units, or group cost allocations.

Other Operating Income Declined from £6.1M (2023) to £4.66M (2024). This income stream requires understanding—is it sustainable, or does it represent one-off group recharges?

4. Monitoring Points

Priority Metrics: 1. Profit sustainability – The 61% PBT decline must be stabilised; request management explanation and forward projections 2. Administrative cost control – The doubling of admin expenses needs justification; establish whether this is investment-related or structural 3. Creditor payment days – At 136 days, monitor for deterioration that could signal cash stress or supplier disputes 4. Inter-company balances – Quantify exposure to group entities; assess recoverability and terms 5. Revenue trajectory – Slight revenue decline in 2024; monitor for further erosion

Structural Considerations: - Verify the financial strength of Inceptua SA (parent) given the cost allocation agreement dependency - Assess the performance of Early Access and Inceptua Pharma units—these appear to be growth investments - No dividends declared—positive for debt servicing capacity - Clean audit opinion with no going concern qualifications—favourable

Recommended Covenant Structure: - Minimum net current assets covenant - Profit before tax floor covenant - Limit on shareholder/director withdrawals - Group support letter where parent guarantees are available